Hyperglycaemia as a Significant Risk Factor in Medication-Related Osteonecrosis of the Jaw (Mronj
Kammerhofer Gábor
Fogorvostudományi Tagozat
Dr. Varga Gábor
SE Szemészeti Klinika Mária utcai tanterme
2026-10-22 10:00:00
Fogorvostudományi kutatások
Dr. Varga Gábor
Dr. Németh Zsolt, Dr. Végh Dániel
Dr. Dános Kornél
Dr. Ferenczi Örs
Dr. Gerber Gábor
Dr. Erdei Csilla
Dr. Oberna Ferenc
This doctoral research investigated the relationship between hyperglycaemia and MRONJ and provides evidence that impaired glucose metabolism represents an important contributing factor in both the development and recurrence of the disease. The findings indicate that disturbances in glucose homeostasis may adversely affect jawbone healing and remodelling, thereby increasing susceptibility to MRONJ and unfavourable clinical outcomes. In particular, dysglycaemic patients demonstrated a higher prevalence of MRONJ and a greater likelihood of recurrence following surgical treatment. The results highlight the importance of incorporating metabolic assessment into routine dental and oral surgical care, especially in patients receiving antiresorptive or antiangiogenic therapy. Comprehensive patient evaluation should include not only dental and medical history but also assessment of glycaemic status and other relevant systemic risk factors. Early identification of hyperglycaemia may facilitate more accurate risk stratification and support the implementation of preventive measures before invasive dentoalveolar procedures. The studies included in this dissertation further demonstrate that preventive dental care, careful treatment planning and structured postoperative follow-up remain essential components of MRONJ prevention and management. Patients with DM, IFG or other disturbances of glucose metabolism represent a particularly vulnerable subgroup that may benefit from closer monitoring and individualized treatment approaches. As the prevalence of DM and hyperglycaemia continues to increase worldwide and the use of antiresorptive and antiangiogenic therapies expands with advances in modern oncology and osteoporosis management, the clinical burden of MRONJ is expected to grow. These developments underscore the importance of improving professional awareness and strengthening interdisciplinary collaboration among dentists, oral and maxillofacial surgeons, diabetologists, endocrinologists, oncologists and primary care physicians. Such cooperation will be essential for optimizing prevention, facilitating early diagnosis and improving outcomes in patients at increased risk of MRONJ.
